



Orion Pharma Limited

Registered Office: Orion House, 153-154 Tejgaon I/A
Dhaka - 1208

Un-Audited 3rd Quarterly (Q3) Financial Statements

This is to inform all concerned that, in Board Meeting held on April 29, 2026 at 4:00 p.m. in the registered office at Orion House, 153-154 Tejgaon I/A, Dhaka - 1208, the Board of Directors of Orion Pharma Limited has adopted its Un-audited 3rd Quarterly (Q3) Financial Statements for the period ended March 31, 2026:

For the Period		July 2025 to March 2026	July 2025 to March 2025	January- March 2026	January- March 2025
Consolidated Earnings Per Share (EPS) - Q3	:	BDT (0.95)	BDT (0.18)	BDT (0.65)	BDT 0.02
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT 4.06	BDT 5.27	--	--
Particulars		March 31, 2026		June 30, 2025	
Consolidated Net Asset Value (NAV) per Share (Including Revaluation Surplus)	:	BDT 85.46		BDT 86.09	
Consolidated Net Asset Value (NAV) per Share (Excluding Revaluation Surplus)	:	BDT 77.72		BDT 78.34	

Dated: April 29, 2026
Tejgaon, Dhaka

By the order of the Board
Sd/-
Md. Ferdous Jaman
Company Secretary